{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"submitter":["Single Cell Omics Platform CBMR"],"organism":["Rattus norvegicus"],"software":["nf-core/rnaseq: 3.12.0"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16695"],"description":["This study evaluates whether simultaneously activating five key metabolic hormone receptors can outperform current peptide therapies for obesity. Using diet‑induced obese rats, we test the combined administration of retatrutide, a GLP‑1, GIP, and glucagon triagonist, together with cagrilintide, an amylin and calcitonin receptor agonist, versus its monotherapies and evaluate the bulk transcriptomic profile of the hypothalamus and the dorsal vagal complex."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Sample Collection - The termination was performed by decapitation for blood and tissue collection. Microdissections of the hypothalamus and dorsal vagal complex (DVC) was performed for RNA isolation and subsequent sequencing.","Nucleic Acid Extraction - For RNA extraction, all tissues were homogenized in TRIzol reagent (QIAzol Lysis Reagent, Qiagen, 79306) with a stainless-steel bead (Qiagen, 69989) using a TissueLyser II (Qiagen, 85300) set at 30 Hz for 3 min. Total RNA was isolated according to the manufacturer's protocol using QIAwave RNA Mini Kit (Qiagen, 74534) and RNA was quantified and RNA quality accessed using NanoDrop 2000 (Thermo Fischer, ND-2000). Total RNA was then converted to cDNA by mixing with FS buffer (Thermo Fisher Scientific, 18080-044), dithiothreitol (Thermo Fisher Scientific, 18080-044) and random primers (Sigma-Aldrich, 11034731001) followed by incubation at 70 oC for 3 min in a thermal cycler (Eppendorf Mastercycler Pro) for first strand synthesis. dNTPs (Thermo Fisher Scientific, R0192)","Growth Protocol - Male Sprague Dawley rats were maintained on ad libitum high-fat, high-sucrose diet (HFHS, 59 kcal% fat, #E15772-347, ssniff spezialdiäten GmbH) from 10 weeks of age and for a minimum of 12 weeks. Rats had an average body weight of >700g before initiating pharmacological studies. The rats were double-housed (Department of Experimental Medicine Rigshospitalet Unit) in a humidity- (45-65%) and temperature-controlled environment (21-23 oC) with a 12-hour light/dark cycle (6:00 am – 6:00 pm).","Sequencing - 52-bp paired-end sequencing on a NovaSeq6000 sequencer","Sample Treatment - At an age of 23 weeks, DIO rats weighing 720g on average were divided into four experimental groups (n = 10): vehicle, 5 nmol kg-1 cagrilintide or retatrutide, and the loose equimolar combination of cagrilintide and retatrutide administered in a single dose. HFHS diet intake was measured and replenished daily for ad libitum feeding followed by measurements of body weight and s.c. o.d. compound administration for 16 days.","Library Construction - Libraries were prepared using the Universal Plus mRNA-seq with NuQuant protocol (Tecan) as recommended by the manufacturer. Libraries were quantified with NuQuant using the CLARIOstar Plate Reader (BMG Labtech) and quality checked using a TapeStation instrument (Agilent Technologies)"],"figure_sub":["Organization","MINSEQE Score","Assays and Data","Processed Data","MAGE-TAB Files"],"data_protocol":["Sequence Alignment - FASTQ-files were analyzed using the nf-core/rnaseq: 3.12.0 with the flags --with_umi --skip_umi_extract --umitools_umi_separator \\\":\\\" agains the rn7 genome and the ENSEMBL release 112 gene model.","Data Transformation - Uploaded data is raw reads, each row is a gene and each column is a sample. No normalization has been performed."],"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"instrument_platform":["Illumina NovaSeq 6000"],"study_type":["RNA-seq of coding RNA"],"species":["Rattus norvegicus"],"pubmed_authors":["Single Cell Omics Platform CBMR","Shad Hassan"],"additional_accession":[]},"is_claimable":false,"name":"Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese rats","description":"This study evaluates whether simultaneously activating five key metabolic hormone receptors can outperform current peptide therapies for obesity. Using diet‑induced obese rats, we test the combined administration of retatrutide, a GLP‑1, GIP, and glucagon triagonist, together with cagrilintide, an amylin and calcitonin receptor agonist, versus its monotherapies and evaluate the bulk transcriptomic profile of the hypothalamus and the dorsal vagal complex.","dates":{"release":"2026-07-20T00:00:00Z","modification":"2026-07-20T11:23:55.172Z","creation":"2026-02-27T09:16:00.1Z"},"accession":"E-MTAB-16695","cross_references":{"ENA":["ERP189703"],"EFO":["EFO_0002944","EFO_0004170","EFO_0003789","EFO_0004917","EFO_0005518","EFO_0003816","EFO_0003738","EFO_0004184","EFO_0003969"]}}